# Immunotherapy via engineered therapeutic programs in tumors using RNA

> **NIH NIH U01** · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $626,885

## Abstract

Immunotherapy treatments such as checkpoint blockade and chimeric antigen receptor T cell therapy have
demonstrated the power of the immune system to eradicate metastatic cancer, but the efficacy of
immunotherapies in solid tumors remains confined to a minority of patients. A series of interlinked events are
needed for efficacy – including induction of immunogenic tumor cell death, recruitment of immune cells to the
tumor bed, and reversion of immunosuppressive cues in the tumor microenvironment (TME). We have
developed a therapeutic approach using intratumorally-administered synthetic lipid nanoparticles (LNPs) to
deliver self-replicating (replicon) RNAs to tumors that activate innate immune signaling pathways and potently
express therapeutic payloads. As shown in our recently published preliminary data, this approach elicited
profound anti-tumor immune responses in several tumor models, and enabled tumor regression of both
injected and distal non-injected tumors. Here we bring together a strong interdisciplinary team to build on these
initial findings and apply a synthetic biology toolkit to create next-generation LNP-replicon therapeutics, which
combine multiple features to increase the safety and efficacy of this approach, including: (1) cell classifier
circuits that allow replicon expression only in target cancer cells or immune cells, (2) optimized multi-
subgenomic promoter replicons that encode multiple payload genes expressed at tunable predefined
expression levels, and (3) small molecule-regulated replicons that allow two-stage therapeutic programs to be
implemented following a single intratumoral injection. These engineered RNAs will be combined with optimized
LNP formulations that promote efficient transfection of desired target cell types in the TME. We will apply this
technology to treat the leading cause of cancer death, lung cancer, and assess its impact using a syngeneic
mouse model of local intratumoral therapy in orthotopic and autochthonous lung cancer models that
recapitulate the TME of human lung cancers. Our specific aims are: (1) Develop formulations for cell type-
specific expression in cancer cells and T cells, (2) Create small molecule-regulated RNA circuits for cancer
cells and T cells for programmable immunogenic cancer cell death and specifically expression in T cells. (3)
Therapeutic testing of optimized replicon circuits in orthotopic lung cancer models alone and in combination.
Altogether, this proposal brings together a highly interdisciplinary team, marrying cutting edge concepts from
synthetic biology and cancer immunotherapy to achieve a more effective, safe, and scalable form of
immunotherapy.

## Key facts

- **NIH application ID:** 10491263
- **Project number:** 5U01CA265706-02
- **Recipient organization:** MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- **Principal Investigator:** Yizhou Dong
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $626,885
- **Award type:** 5
- **Project period:** 2021-09-20 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10491263

## Citation

> US National Institutes of Health, RePORTER application 10491263, Immunotherapy via engineered therapeutic programs in tumors using RNA (5U01CA265706-02). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10491263. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*